

Table of Compounds for Drug Repurposing Collaboration Pilot Project

◎請點選下列化合物編號即可連結至該化合物詳細敘述

Compound	Mechanism of Action	Original Indication	Route of Administration (CNS Penetrant)	Type of Proposals Invited
AZD5363*	AKT serine/threonine protein kinase (also known as protein kinase B alpha) inhibitor	Oncology	Oral	Preclinical
AZD1981	Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist]	Asthma, COPD	Oral (Low)	Clinical and/or Preclinical
ZD4054 (zibotentan)	Endothelin receptor A (ETA) antagonist	Oncology	Oral (Low)	Clinical and/or Preclinical
AZD7325	Gamma-aminobutyric acid receptor A alpha 2 and 3 (GABAA α 2,3) positive modulator	General Anxiety Disorder	Oral (Yes)	Clinical and/or Preclinical
AZD3355 (lesogaberan)	Gamma-aminobutyric acid receptor B (GABAB) agonist	GERD	Oral (Low)	Clinical and/or Preclinical
AZD1656	Glucokinase (GK; hexokinase 4) activator	Diabetes	Oral (Low)	Clinical and/or Preclinical
AZD5213*	Histamine receptor 3 (H ₃) antagonist (inverse agonist)	Cognition, Daytime Sleepiness, Tourette's	Oral (Yes)	Clinical and/or Preclinical
AZD4017	11-beta-hydroxysteroid dehydrogenase type 1 (11 β -HSD1) inhibitor	Diabetes	Oral (Low)	Clinical and/or Preclinical
AZD8329*	11-beta-hydroxysteroid dehydrogenase type 1 (11 β -HSD1) inhibitor	Diabetes	Oral (Low)	Preclinical
MEDI2338	Interleukin-18 neutralizing monoclonal antibody (α IL-18 mAb)	COPD, CHD	Intravenous	Clinical and/or Preclinical
AZD1236	Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor	COPD	Oral (Low)	Clinical and/or Preclinical
AZD8529	Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator	Schizophrenia	Oral (Yes)	Clinical and/or Preclinical

<u>AZD5904</u>	Myeloperoxidase (MPO) inhibitor	COPD, MS	Oral (Low)	Clinical and/or Preclinical
<u>AZD2624*</u>	Neurokinin-3 receptor; Tachykinin receptor 3 (NK3R; TACR3) antagonist	Schizophrenia	Oral (Low)	Clinical and/or Preclinical
<u>AZD9668</u>	Neutrophil elastase (NE) inhibitor	COPD, Cystic Fibrosis	Oral (Low)	Clinical and/or Preclinical
<u>AZD0328</u>	Nicotinic acetylcholine receptor alpha 7 ($\alpha 7$ nAChR) agonist	Cognitive impairment	Oral (Yes)	Clinical and/or Preclinical
<u>AZD8186*</u>	Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit beta (PIK3CB; PI3K β) and delta (PIK3CD; PI3K δ) inhibitor	Oncology	Oral	Preclinical
<u>AZ11657312*</u>	Purinergic receptor 2X, ligand-gated ion channel 7 (P2X ₇) antagonist	COPD, Crohn's, OA, RA	Oral (Low)	Preclinical
<u>AZD0530</u> (saracatinib)	Src tyrosine kinase family inhibitor	Oncology	Oral (Low)	Clinical and/or Preclinical
<u>AZD2171</u> (cediranib)	Vascular endothelial growth factor receptor 1, 2 & 3 (VEGFR1,2,3), c-Kit & PDGFR β tyrosine kinase inh.	Oncology	Oral (?)	Clinical and/or Preclinical

備註：有標註星號(*)為 10 月 11 日新增之項目，為藥廠現正發展中之化合物(live compounds)。